DOI:
10.1055/s-00000071
Seminars in Neurology
LinksClose Window
References
Cree BAC, Bennett JL, Kim HJ. et al; N-MOmentum study investigators.
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
Lancet 2019;
394 (10206): 1352-1363
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.